RE:RE:RE:RE:RE:RE:RE:RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsJanuary 31, 2023 - Unprecedently the FDA granted Pfizer's Ibrance (CDK4/6 inhibitor) a marketing approval in ER+/HER2 negative (HR+/HER2 negative) metastatic breast cancer patients in combination with aromatase inhibitors regardless of menopaual status.
Pfizer's Ibrance currently hold an FDA approval for Ibrance + aromatase inhibitors in patients with post-menopausal metastatic breast cancer.
This development does not impact Ibrance's looming patent loss in March 2027.
This however further positions ONCY's pelareorep in combination with Pfizer's Ibrance (CDK 4/6 inhibitor) + immune checkpoint inhibitors (i.e. Pfizer/Merck KGaA's Bavencio and Pfizer's investigational checkpoint inhibitors).
https://www.fiercepharma.com/pharma/mysterious-approval-pfizer-quietly-wins-ibrance-breast-cancer-expansion-after-fda-requested